Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Microbial Immunity and Vaccines

Porphyromonas gingivalis-Specific Immunoglobulin G Prevents P. gingivalis-Elicited Oral Bone Loss in a Murine Model

Frank C. Gibson III, Dario A. Gonzalez, Jodie Wong, Caroline Attardo Genco
Frank C. Gibson III
1Department of Medicine, Section of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dario A. Gonzalez
2Department of Oral Biology and Periodontology, Goldman School of Dental Medicine, Boston University Medical Center, Boston, Massachusetts 02118
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jodie Wong
2Department of Oral Biology and Periodontology, Goldman School of Dental Medicine, Boston University Medical Center, Boston, Massachusetts 02118
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Attardo Genco
1Department of Medicine, Section of Infectious Diseases
2Department of Oral Biology and Periodontology, Goldman School of Dental Medicine, Boston University Medical Center, Boston, Massachusetts 02118
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: caroline.genco@bmc.org
DOI: 10.1128/IAI.72.4.2408-2411.2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Active immunization with Porphyromonas gingivalis whole-cell preparations has been shown to prevent P. gingivalis infection and oral bone loss. Employing passive antibody transfer and opsonization, we demonstrate with this study that immunization-elicited P. gingivalis-specific immunoglobulin G facilitates clearance of P. gingivalis in a subcutaneous chamber model and prevents P. gingivalis-elicited oral bone loss.

Epidemiological data indicate that by age 35 approximately 30% of the U.S. adult population suffers from periodontal disease (17), a chronic inflammatory disease of the hard and soft tissues supporting the teeth that in severe cases leads to tooth loss. Most cases of this disease are caused by the anaerobic bacterial pathogen Porphyromonas gingivalis (13, 18). Numerous studies have assessed the serum antibody profiles of patients with periodontitis. High levels of P. gingivalis-specific immunoglobulin G (IgG) are commonly observed (12, 19), yet a variable host response to this organism appears to exist (1, 11, 14, 16). However, despite this potent antibody response the host is apparently unable to clear this chronic infection. Notwithstanding this fact, Wilton et al. (20) reported that sera obtained from patients with periodontal disease contain antibodies that promote opsonophagocytosis of P. gingivalis by human neutrophils.

Previous reports suggest that vaccination affords protection from P. gingivalis infection (3, 5-7, 9, 10, 15). Gibson et al. (7) demonstrated that immunization of mice with heat-killed P. gingivalis elicited high levels of specific IgG and protected mice from subsequent oral bone loss elicited by this organism. Employing both murine subcutaneous chamber and oral challenge models, we demonstrate in this study that prevention of P. gingivalis infection occurs with immunization-elicited P. gingivalis-specific IgG.

P. gingivalis strain A7436 was used in all of our studies. This organism was initially cultivated on anaerobic blood agar plates, and bacteria were havested by centrifugation and grown in brain heart infusion (BHI) broth overnight. P. gingivalis organisms were collected and suspended in fresh BHI broth to a final cell density of 109 CFU/ml (7). Heat-killed P. gingivalis and formaldehyde-fixed P. gingivalis were prepared as described previously (7). BALB/C mice (Jackson Laboratories, Bar Harbor, Maine) were immunized subcutaneously with heat-killed P. gingivalis whole-organism preparations three times per week for 3 weeks, and the mice were exsanguinated. Serum was applied to a Protein G column (Amersham Pharmacia Biotech, Uppsala, Sweden) and total IgG was eluted (approximately 50 mg); the result was designated P. gingivalis-specific IgG. Using enzyme-linked immunosorbent assay, we observed that the titer of the P. gingivalis-specific IgG was 1:50,000 (data not shown). A commercially obtained mouse IgG (irrelevant IgG [IRR-IgG]; Sigma, St. Louis, Mo.) was used as an IgG control. For passive transfer studies, mice received an injection of 100 μl of P. gingivalis-specific IgG or IRR-IgG (1 mg/ml) in the subcutaneous chamber 24 h prior to P. gingivalis challenge. In addition, P. gingivalis was opsonized with either 100 μg of P. gingivalis-specific IgG or IRR-IgG per ml. The effect of opsonization on P. gingivalis viability was assessed by determination of CFU per milliliter and did not affect P. gingivalis viability.

Initially, we assessed the protective capacity of P. gingivalis-specific IgG by using a murine subcutaneous chamber model (4). Mice were separated into six groups (n = 8 mice/group). Group 1 received 0.1 ml of sterile BHI broth only (vehicle), group 2 received 0.1 ml of P. gingivalis in vehicle (∼108 CFU), groups 3 and 4 received passive transfer of P. gingivalis-specific IgG or IRR-IgG, respectively, and groups 5 and 6 were challenged with P. gingivalis opsonized with P. gingivalis-specific IgG or IRR-IgG. Following challenge, mice were examined daily for signs of infection, including cachexia (defined as ruffled hair), hunched bodies, weakness, and lethargy, as well as for the presence of primary and secondary lesions. Animals in group 2 exhibited signs of severe cachexia and presented with chamber lesions that eventually resulted in chamber rejection by day 10 (Table 1), while mice in group 1 appeared healthy. Passive immunization (group 3) or opsonization of P. gingivalis with P. gingivalis-specific IgG (group 5) protected mice from all signs of P. gingivalis infection (Table 1). In contrast, animals from groups 4 and 6 were not protected and resembled mice from group 2 (Table 1).

A sample of chamber fluid (50 μl) was collected from each animal at 1, 3, 7, and 10 days post-P. gingivalis challenge to assess bacterial replication and the inflammatory response. A 10-μl aliquot of each chamber fluid sample was serially 10-fold diluted in 1% peptone and plated onto anaerobic blood agar plates, and the number of CFU of P. gingivalis per milliliter was determined. Chamber fluid samples obtained from mice in group 2 demonstrated that P. gingivalis was capable of replication and persistence throughout the 10-day period (Fig. 1). Analysis of chamber fluid samples obtained from group 3 mice revealed that P. gingivalis was readily cleared, with no viable organisms recovered by day 7 (Fig. 1). Animals from group 5 also efficiently cleared P. gingivalis. Mice in groups 4 and 6 failed to clear P. gingivalis and resembled animals that had been challenged with P. gingivalis alone (Fig. 1). These data demonstrate that passive transfer of immunization-elicited P. gingivalis-specific IgG facilitates clearance of P. gingivalis in a virulence model. An additional 10-μl aliquot from each chamber fluid sample was used to determine the total inflammatory cell count by trypan blue staining. Animals from group 1 possessed relatively few inflammatory cells. By day 3, the levels of inflammatory cells present in chamber fluids of mice in group 2 were elevated and remained higher throughout the remainder of the experiment (Fig. 2). The inflammatory cell responses of mice from groups 3 and 5 were reduced by day 3 and resembled those of mice in group 1 at days 7 and 10, while mice from groups 4 and 6 possessed levels of inflammatory cells that resembled those of mice in group 2 (Fig. 2). These data support the supposition that P. gingivalis infection is controlled in mice that received P. gingivalis-specific IgG, as the cellular inflammatory response of mice challenged with P. gingivalis is resolved following clearance of bacteria.

We also employed a modified version of the fluorescent microscopic opsonophagocytosis assay of Kalmer et al. (8) and Cutler et al. (2) to assess the interaction of the inflammatory cells and P. gingivalis in the murine chamber fluid samples. In brief, a 10-μl aliquot of each chamber fluid sample was diluted to 1:50 in sterile phosphate-buffered saline; was incubated with 4′6′-diamidino-2-phenylindole (DAPI; 5 μg/ml, Sigma), propidium iodine (5 μg/ml, Sigma), and acridine orange (2.5 mM, Sigma); and was cytocentrifuged onto a glass slide. The polymorphonuclear leukocyte (PMN) viability, the ratio of the number of P. gingivalis organisms to the number of PMN (P. gingivalis/PMN), and the percentage of PMNs with at least one P. gingivalis organism were determined in blinded fashion. Mice challenged with P. gingivalis had approximately 20% dead PMNs present in the chamber fluid samples at day 1 postchallenge. Interestingly, the percentage of dead PMNs present in chamber fluid samples of mice from groups 3 and 5 was significantly reduced compared with that of group 2 animals (P < 0.05, data not shown). Passive transfer (group 4) or opsonization with IRR-IgG (group 6) failed to prevent PMN death in response to P. gingivalis challenge, as the PMN viability results resembled those of mice in group 2.

We also recorded the number of P. gingivalis/PMN as well as the percentage of phagocytosis from the murine chamber fluid samples (Table 2). At day 1, we observed that approximately half of the PMNs in the chamber fluid samples of group 2 mice possessed bacteria and that each had approximately five associated P. gingivalis organisms. Unexpectedly, the mice from group 3 possessed fewer P. gingivalis/PMN and had a reduced percentage of phagocytosis compared with that of group 4 (Table 2). Opsonization of P. gingivalis with P. gingivalis-specific IgG (group 5) resulted in an increased number of P. gingivalis/PMN compared to that found in group 2; however, this level was only approximately half the number of P. gingivalis/PMN compared to that of the group 6 mice. At day 3, we observed that approximately 40% of the PMNs were actively participating in phagocytosis of P. gingivalis, with nearly four bacteria per PMN in group 2. Chamber fluids of the mice in group 3 presented with more bacteria within each PMN compared with results for group 2 or group 4 (Table 2). Similarly, we observed that group 5 facilitated P. gingivalis uptake by PMNs compared with results for the IRR-IgG opsonization group (group 6). These data support our supposition that P. gingivalis is actively taken up by PMNs in the presence of specific IgG.

Finally, the murine oral challenge model was employed to assess the impact of P. gingivalis-specific IgG opsonization on P. gingivalis-elicited oral bone loss (7). Eight mice were included in each group. Group 1 was not treated and served as the controls, group 2 was gavaged with 100 μl of live P. gingivalis in carboxymethyl cellulose, group 3 was gavaged with P. gingivalis opsonized with IRR-IgG, and group 4 was gavaged with P. gingivalis opsonized with P. gingivalis-specific IgG. Mice in group 2 developed significant maxillary molar bone loss compared with that of group 1 (P < 0.05; Fig. 3). Mice in group 4 were protected from oral bone loss (P < 0.05) and resembled group 1 mice (P > 0.2). Mice in group 3 were not protected from oral bone loss and were significantly different from mice in group 4 (P < 0.05; Fig. 3). These data demonstrate that opsonization of P. gingivalis with specific IgG inhibits P. gingivalis-elicited oral bone loss.

To our knowledge, passive antibody transfer studies using both prevention of infection and oral bone loss as end points have not been performed to show that immunization-elicited IgG alone mediates clearance of P. gingivalis in naïve animals. By using both a murine subcutaneous chamber model and an oral bone loss model, the present study demonstrates that immunization-elicited P. gingivalis-specific IgG prevents subsequent P. gingivalis infection. We are continuing to understand the contribution of immunization-elicited IgG to specific P. gingivalis antigens for vaccinology to prevent P. gingivalis-mediated periodontal disease.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Chamber fluid levels of P. gingivalis expressed in terms of CFU per milliliter. Chamber fluids were collected at 1 (solid bar), 3 (speckled bar), 7 (diagonal hatched bar), and 10 (horizontal hatched bar) days postchallenge from groups of mice that were challenged with P. gingivalis (A7436), P. gingivalis following passive antibody transfer of P. gingivalis-specific IgG (Pg-IgG) or IRR-IgG antibody, or P. gingivalis opsonized with P. gingivalis-specific IgG (OPZ Pg-IgG) or IRR-IgG (OPZ IRR-IgG). *, P < 0.05 compared with matched IRR-immunized groups by the Student t test; ND, P. gingivalis not detected in chamber fluid samples.

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

Chamber fluid levels of inflammatory cells as determined by trypan blue vital dye counts. Chamber fluid samples obtained on 1 (solid bar), 3 (speckled bar), 7 (diagonal hatched bar), and 10 (horizontal hatched bar) days postchallenge from groups of mice that were challenged with P. gingivalis (A7436), P. gingivalis following passive antibody transfer of P. gingivalis-specific (P. gingivalis-specific IgG) or irrelevant (IRR-IgG) antibody, or P. gingivalis opsonized with P. gingivalis-specific IgG (OPZ Pg-IgG) or IRR-IgG (OPZ IRR-IgG). The samples were diluted 1:10 with trypan blue vital dye, and the total number of inflammatory cells was determined by using hemocytometer counts. *, P < 0.05 compared with matched IRR-immunized groups by the Student t test.

FIG. 3.
  • Open in new tab
  • Download powerpoint
FIG. 3.

Opsonization of P. gingivalis with P. gingivalis-specific IgG prior to oral challenge inhibits P. gingivalis-elicited oral bone loss. Groups of BALB/C mice were either unchallenged (None), were orally challenged with P. gingivalis (A7436), or were gavaged with P. gingivalis opsonized with control IRR-IgG or P. gingivalis-specific IgG. Linear measurements were obtained from the cementum-enamel junction to the alveolar bone crest from the maxillary molars at 14 landmark sites per mouse. *, P < 0.05 by the Student t test versus control mice (None); NS, not significant versus control (None).

View this table:
  • View inline
  • View popup
TABLE 1.

Gross pathological observations of mice passively immunized or opsonized with P. gingivalis-specific IgG and challenged with P. gingivalis in a murine subcutaneous chamber modela

View this table:
  • View inline
  • View popup
TABLE 2.

Assessment of the interaction of P. gingivalis with murine inflammatory cells in murine chamber fluids by fluorescent microscopya

ACKNOWLEDGMENTS

This work was supported by NIH grants F32-DE05326 (F.C.G.) and R01-DE12517 (C.A.G.).

FOOTNOTES

    • Received 1 August 2003.
    • Returned for modification 1 October 2003.
    • Accepted 2 January 2004.
  • Copyright © 2004 American Society for Microbiology

REFERENCES

  1. 1.↵
    Califano, J. V., R. E. Schifferle, J. C. Gunsolley, A. M. Best, H. A. Schenkein, and J. G. Tew. 1999. Antibody reactive with Porphyromonas gingivalis serotypes K1-6 in adult and generalized early-onset periodontitis. J. Periodontol.70:730-735.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Cutler, C. W., J. R. Kalmar, and R. R. Arnold. 1991. Phagocytosis of virulent Porphyromonas gingivalis by human polymorphonuclear leukocytes requires specific immunoglobulin G. Infect. Immun.59:2097-2104.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Evans, R. T., B. Klausen, and R. J. Genco. 1992. Immunization with fimbrial protein and peptide protects against Porphyromonas gingivalis-induced periodontal tissue destruction. Adv. Exp. Med. Biol.327:255-262.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Genco, C. A., C. W. Cutler, D. Kapczynski, K. Maloney, and R. R. Arnold. 1991. A novel mouse model to study the virulence of and host response to Porphyromonas (Bacteroides) gingivalis.Infect. Immun.59:1255-1263.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Genco, C. A., D. R. Kapczynski, C. W. Cutler, R. J. Arko, and R. R. Arnold. 1992. Influence of immunization on Porphyromonas gingivalis colonization and invasion in the mouse chamber model. Infect. Immun.60:1447-1454.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    Genco, C. A., B. M. Odusanya, J. Potempa, J. Mikolajczyk-Pawlinska, and J. Travis. 1998. A peptide domain on gingipain R which confers immunity against Porphyromonas gingivalis infection in mice. Infect. Immun.66:4108-4114.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Gibson, F. C., III, and C. A. Genco. 2001. Prevention of Porphyromonas gingivalis-induced oral bone loss following immunization with gingipain R1. Infect. Immun.69:7959-7963.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Kalmar, J. R., R. R. Arnold, and T. E. van Dyke. 1987. Direct interaction of Actinobacillus actinomycetemcomitans with normal and defective (LJP) neutrophils. J. Periodontal Res.22:179-181.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Katz, J., K. P. Black, and S. M. Michalek. 1999. Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model. Infect. Immun.67:4352-4359.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Kuboniwa, M., A. Amano, S. Shizukuishi, I. Nakagawa, and S. Hamada. 2001. Specific antibodies to Porphyromonas gingivalis Lys-gingipain by DNA vaccination inhibit bacterial binding to hemoglobin and protect mice from infection. Infect. Immun.69:2972-2979.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Lopatin, D. E., and E. Blackburn. 1992. Avidity and titer of immunoglobulin G subclasses to Porphyromonas gingivalis in adult periodontitis patients. Oral Microbiol. Immunol.7:332-337.
    OpenUrlPubMed
  12. 12.↵
    Mooney, J., and D. F. Kinane. 1994. Humoral immune responses to Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans in adult periodontitis and rapidly progressive periodontitis. Oral Microbiol. Immunol.9:321-326.
    OpenUrlPubMed
  13. 13.↵
    Nonnenmacher, C., R. Mutters, and L. F. de Jacoby. 2001. Microbiological characteristics of subgingival microbiota in adult periodontitis, localized juvenile periodontitis and rapidly progressive periodontitis subjects. Clin. Microbiol. Infect.7:213-217.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    O'Brien-Simpson, N. M., C. L. Black, P. S. Bhogal, S. M. Cleal, N. Slakeski, T. J. Higgins, and E. C. Reynolds. 2000. Serum immunoglobulin G (IgG) and IgG subclass responses to the RgpA-Kgp proteinase-adhesin complex of Porphyromonas gingivalis in adult periodontitis. Infect. Immun.68:2704-2712.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    O'Brien-Simpson, N. M., R. A. Paolini, and E. C. Reynolds. 2000. RgpA-Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model. Infect. Immun.68:4055-4063.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Ogawa, T., Y. Kono, M. L. McGhee, J. R. McGhee, J. E. Roberts, S. Hamada, and H. Kiyono. 1991. Porphyromonas gingivalis-specific serum IgG and IgA antibodies originate from immunoglobulin-secreting cells in inflamed gingiva. Clin. Exp. Immunol.83:237-244.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    Oliver, R. C., L. J. Brown, and H. Loe. 1998. Periodontal diseases in the United States population. J. Periodontol.69:269-278.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Page, R. C., L. C. Altman, J. L. Ebersole, G. E. Vandesteen, W. H. Dahlberg, B. L. Williams, and S. K. Osterberg. 1983. Rapidly progressive periodontitis. A distinct clinical condition. J. Periodontol.54:197-209.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Whitney, C., J. Ant, B. Moncla, B. Johnson, R. C. Page, and D. Engel. 1992. Serum immunoglobulin G antibody to Porphyromonas gingivalis in rapidly progressive periodontitis: titer, avidity, and subclass distribution. Infect. Immun.60:2194-2200.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Wilton, J. M., T. J. Hurst, and J. A. Sterne. 1993. Elevated opsonic activity for Porphyromonas (Bacteroides) gingivalis in serum from patients with a history of destructive periodontal disease: a case control study. J. Clin. Periodontol.20:563-569.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Porphyromonas gingivalis-Specific Immunoglobulin G Prevents P. gingivalis-Elicited Oral Bone Loss in a Murine Model
Frank C. Gibson III, Dario A. Gonzalez, Jodie Wong, Caroline Attardo Genco
Infection and Immunity Mar 2004, 72 (4) 2408-2411; DOI: 10.1128/IAI.72.4.2408-2411.2004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Porphyromonas gingivalis-Specific Immunoglobulin G Prevents P. gingivalis-Elicited Oral Bone Loss in a Murine Model
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Porphyromonas gingivalis-Specific Immunoglobulin G Prevents P. gingivalis-Elicited Oral Bone Loss in a Murine Model
Frank C. Gibson III, Dario A. Gonzalez, Jodie Wong, Caroline Attardo Genco
Infection and Immunity Mar 2004, 72 (4) 2408-2411; DOI: 10.1128/IAI.72.4.2408-2411.2004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

alveolar bone loss
Antibodies, Bacterial
Bacterial Vaccines
Disease Models, Animal
Immunoglobulin G
periodontitis
Porphyromonas gingivalis

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522